Kailera Therapeutics, Inc. (KLRA) Balance Sheet
KLRA balance sheet, 2025
December 31, 2025 · U.S. dollars$692.3M assets = $1.05B liabilities + −$356.5M equity
Liabilities exceed assets: shareholders’ equity is negative (−$356.5M).
Both columns are drawn to the same scale: what KLRA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
KLRA financial health
Descriptive bands, not a rating. Fiscal 2025.
KLRA balance sheet trends, 2024–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $178.4M2024 | $692.3M2025 | +288.0%/yr | |
| Total liabilities | $397.2M2024 | $1.05B2025 | +164.0%/yr | |
| Shareholders’ equity | −$218.8M2024 | −$356.5M2025 | — | |
| Cash & short-term investments | $175.2M2024 | $546.1M2025 | +211.7%/yr | |
| Working capital | $170.7M2024 | $511.1M2025 | +$340.4M | |
| Book value per share | −$1.852024 | −$3.022025 | — | |
| Shares outstanding | 117.9M2024 | 117.9M2025 | 0.0%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
KLRA assets
KLRA liabilities and equity
KLRA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
KLRA balance sheet
| 2025 | 2024 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $546.1M | $175.2M |
| Cash & equivalents | $160.3M | $175.2M |
| Short-term investments | $385.8M | $0 |
| Receivables | $2.7M | $0 |
| Inventory | $0 | $0 |
| Other current assets | $8.8M | $2.4M |
| Total current assets | $557.5M | $177.6M |
| Property, plant & equipment (net) | $12.4M | $680,000 |
| Goodwill & intangible assets | $0 | $0 |
| Long-term investments | $106.7M | $0 |
| Other non-current assets | $15.7M | $154,000 |
| Total assets | $692.3M | $178.4M |
| Liabilities | ||
| Accounts payable | $7.5M | $2.0M |
| Short-term debt | $1.0M | — |
| Total current liabilities | $46.4M | $6.9M |
| Long-term debt | $0 | $0 |
| Lease obligations | $10.8M | $509,000 |
| Other long-term liabilities | $1.00B | $390.3M |
| Total liabilities | $1.05B | $397.2M |
| Shareholders' equity | ||
| Retained earnings (deficit) | −$368.7M | −$219.7M |
| Accumulated other comprehensive income | $229,000 | — |
| Total shareholders' equity | −$356.5M | −$218.8M |
| Key figures | ||
| Total debt | $10.8M | — |
| Net cash (debt) | $535.3M | — |
| Working capital | $511.1M | $170.7M |
| Tangible book value | −$356.5M | −$218.8M |
| Book value per share | −$3.02 | −$1.85 |
| Shares outstanding | 117.9M | 117.9M |
| Current ratio | 12.01 | 25.70 |
| Quick ratio | 11.83 | 25.35 |
| Equity / assets | −51.5% | −122.6% |
| Jun '26 | Mar '26 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $916.7M | $519.2M |
| Cash & equivalents | $130.3M | $111.8M |
| Short-term investments | $786.4M | $407.3M |
| Receivables | $6.1M | $3.2M |
| Inventory | $0 | $0 |
| Other current assets | $6.3M | $7.9M |
| Total current assets | $929.2M | $530.3M |
| Property, plant & equipment (net) | $11.7M | $12.0M |
| Goodwill & intangible assets | $0 | $0 |
| Long-term investments | $255.1M | $62.7M |
| Other non-current assets | $15.5M | $19.7M |
| Total assets | $1.21B | $624.8M |
| Liabilities | ||
| Accounts payable | $19.2M | $7.1M |
| Short-term debt | $1.1M | $1.0M |
| Total current liabilities | $83.7M | $54.8M |
| Long-term debt | $0 | $0 |
| Lease obligations | $10.2M | $10.5M |
| Other long-term liabilities | $9.3M | $1.00B |
| Total liabilities | $93.0M | $1.06B |
| Shareholders' equity | ||
| Retained earnings (deficit) | −$558.8M | −$447.5M |
| Accumulated other comprehensive income | −$1.8M | −$532,000 |
| Total shareholders' equity | $1.12B | −$432.1M |
| Key figures | ||
| Total debt | $10.2M | $10.5M |
| Net cash (debt) | $906.5M | $508.7M |
| Working capital | $845.5M | $475.5M |
| Tangible book value | $1.12B | −$432.1M |
| Book value per share | $10.94 | −$3.66 |
| Shares outstanding | 102.2M | 117.9M |
| Current ratio | 11.11 | 9.67 |
| Quick ratio | 11.03 | 9.53 |
| Debt / equity | 0.01 | — |
| Equity / assets | 92.3% | −69.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 31, 2025); data from EODHD.
KLRA financial position
At the end of fiscal 2025 (December 31, 2025), Kailera Therapeutics had total assets of $692.3 million (up 288.0% from a year earlier), total liabilities of $1.0 billion and shareholders' equity of -$356.5 million. It held $546.1 million in cash and short-term investments against $10.8 million of debt, a net cash position of $535.3 million. Its current ratio was 12.01. In the latest quarter (ended June 30, 2026) total assets were $1.2 billion and equity $1.1 billion.
Related: KLRA income statement. See the KLRA stock overview for the latest quote and news.
KLRA balance sheet FAQ
What are Kailera Therapeutics's total assets?
Kailera Therapeutics reported total assets of $692.3 million at the end of fiscal 2025 (December 31, 2025), compared with $178.4 million a year earlier.
How much debt does Kailera Therapeutics have?
Kailera Therapeutics had $10.8 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Kailera Therapeutics have?
Kailera Therapeutics held $546.1 million in cash and short-term investments at the end of fiscal 2025; with $10.8 million of debt that is net cash of $535.3 million.
What is Kailera Therapeutics's book value?
Kailera Therapeutics's shareholders' equity (book value) was -$356.5 million at the end of fiscal 2025, or −$3.02 per share.
What is Kailera Therapeutics's current ratio?
Kailera Therapeutics had current assets of $557.5 million and current liabilities of $46.4 million, a current ratio of 12.01 (it can cover its short-term obligations).